SELL (Trim 30-40% of UNH exposure below benchmark weight; do not add at $421; wait for confirmed breakout above $436 or reset to $390-$400)

• Price below 10 EMA, Bollinger midline, AND VWMA simultaneously = classic distribution, not healthy consolidation
• MACD histogram flipped negative for first time in weeks after 75% vertical move from $234 to $436
• RSI at 51 after parabolic run from $234 to $436 signals buyer exhaustion
• 2025 EPS miss of 34%; Q4 2025 net income effectively zero at $10 million on over $100 billion revenue
• Medical cost trend blowouts, Change Healthcare cyberattack aftermath, and MA risk-adjustment headwinds drove the crisis
• $110.5 billion in goodwill vs $105.3 billion total equity is structural risk not priced into P/E models
• 18.8x forward P/E compresses if hawkish regime persists; Polymarket pricing 89% probability of zero Fed cuts in 2026
• If P/E compresses to 16x on $22.44 EPS, stock reaches $359 — 15% drawdown from current levels
• Fair value model revised from $424 to $475 in one week is not a durable floor
• Part D Premium Stabilization locked in for 2027 means no income statement impact until 2027 (current date July 30, 2026)
• Cigna IDR cost commentary signals elevated surprise-billing dispute costs at UNH — a competitor confirming specific cost issues
• Today's volume of 2.84 million shares vs 6-13 million during April-July rally suggests institutional distribution, not shallow dip
• Hard stop at $390 is actually below 50 SMA at $408; true stop is 200 SMA at $341, 19% below current price
• $475 target requires breaking resistance at $436 that has rejected twice already
• Path of least resistance is sideways to down, not upward breakout
• 52-week range of $234 to $461 confirms high volatility and uncertainty
• 15-20% portfolio allocation with $390 stop = 4-5% portfolio loss on single stop-out — reckless concentration
• Conservative sizing prioritizes what happens if wrong, not just if right

→ vs aggressive: Technical indicators (price below 10 EMA, Bollinger midline, VWMA simultaneously) represent classic distribution, not a coiled spring or healthy consolidation; MACD negative for first time in weeks after 75% vertical move signals momentum exhaustion, not overbought reset

→ vs aggressive: Forward P/E of 18.8x is not a gift if forward EPS of $22.44 is not achievable; in hawkish regime with 89% probability of zero Fed cuts, multiples contract not expand; if P/E drops to 16x, stock reaches $359 (15% drawdown), not $449

→ vs aggressive: Fair value model moved from $424 to $475 in one week; same shop can revise it back the other way just as fast if Q3 disappoints; models are outputs of assumptions, not durable floors

→ vs aggressive: Part D Premium Stabilization locked in for 2027 means P&L impact hasn't started to register; we are at July 30, 2026 with 2027 headwinds not yet in earnings; 'priced in' is not a get-out-of-jail-free card

→ vs aggressive: Cigna IDR cost commentary is a competitor voluntarily highlighting UNH's specific cost pressure, not competitive differentiation; this is a signal, not noise, confirming medical cost normalization thesis is not clean

→ vs aggressive: Risk-reward math: stop at $390 is actually below 50 SMA at $408; true technical stop is 200 SMA at $341, which is 19% below current price; target at $475 requires breaking $436 resistance that has rejected twice

→ vs aggressive: 15-20% portfolio allocation is reckless concentration in a stock with 52-week range from $234 to $461 (volatility range screaming uncertainty); stop-out costs 4-5% of total portfolio value on a single trade

TRIM 15-20% of UNH exposure; tighten stop to 50 SMA ($408.86); wait for re-entry at $436 breakout or $390-$400 pullback

• Current price $421 implies ~18.8x forward earnings on $22.44 normalized EPS, above fair value estimate of $400-$410
• Realistic forward multiple range of 17-19x implies price range of $381-$426; current level offers limited upside with asymmetric downside risk
• Technical picture shows confirmed long-term uptrend with short-term momentum cooldown and weak volume at $436 resistance
• The 50 SMA at $408.86 is a meaningful technical level to invalidate short-term uptrend if violated
• Institutional bullish sentiment lacks retail confirmation (missing StockTwits/Reddit data), suggesting fragile sentiment architecture
• Q1 2026 EPS of $6.90 nearly matched Q1 2025's $6.85, and Q2 2026 beat with raised guidance demonstrates business recovery
• UNH's 0.633 beta provides defensive characteristics supporting the multiple in hawkish regime but limits expansion
• The $390 stop is too loose (gives back 7%+), while $390 floor is too tight given normal volatility within uptrend
• 2027 Part D Premium Stabilization headwind is not yet priced into numbers and represents unaddressed regulatory risk
• The 52-week range of $234-$461 and current recovery rally from $234 to $436 creates concentration risk warranting partial trim

→ vs aggressive: Entry point at $421 paying 16% above 50 SMA and 24% above 200 SMA with cooling momentum indicators is a momentum premium, not a structural discount; $475 fair value is a model recalibration not market consensus

→ vs conservative: Triple indicator failure indicates consolidation within a trend, not regime change; $359 target on 16x multiple compression applies worst-case as base case; 30-40% trim is overshooting given intact uptrend and recovery inflection in earnings